PSMA6 and chronic kidney disease: Left ventricular hypertrophy (LVH) is a strong cardiovascular risk marker in end-stage renal disease patients, so we also investigated the association between PSMA6 polymorphism and LVH present in 54 % of our patients (Table 3).